SAIMSARA Journal

Machine Generated Science • ISSN 3054-3991

Anticoagulation in Peripheral Artery Disease: Scoping Review with ☸️SAIMSARA.

Vascular Health icon

Vascular Health

Issue 1, Volume 1, 2026

Chat with this issue

Editorial note
• Last update: 2026-04-04 10:09:18
What is this paper about
This review shows that anticoagulation in PAD is not a simple “more is better” story: low-dose rivaroxaban plus aspirin delivers the clearest reduction in limb and cardiovascular events, but the benefit is tightly linked to patient selection and bleeding risk. The full read is worth it because it maps exactly where dual pathway inhibition is strongest, where full-dose or nonspecific anticoagulation may backfire, and how PAD changes the antithrombotic strategy in real-world settings like revascularization, VTE overlap, and atrial fibrillation.
Found an issue in this paper? Email admin@saimsara.com

DOI: 10.62487/saimsaraac354ec8

Abstract: The aim of this paper is to synthesize current evidence regarding the efficacy, safety, and clinical implementation of anticoagulation in patients with PAD, evaluating the impact of different regimens on limb patency, cardiovascular mortality, and bleeding complications across various clinical settings. The review utilises 110 original studies with 2351292 total participants (topic deduplicated ΣN). The evidence map identifies low-dose rivaroxaban plus aspirin as the most consistent anticoagulation-related signal in PAD, with reported reductions of 24% in MACE and 43% to 47% in MALE, alongside a major bleeding increase with hazard ratios around 1.70 to 1.78. This pattern was most persuasive in symptomatic and post-revascularization PAD, where intensified therapy also appeared to reduce total thrombotic events and venous thromboembolism, supporting a practical role for dual pathway inhibition in carefully selected patients. At the same time, the broader evidence base indicates that full-dose or nonspecific anticoagulation strategies do not uniformly translate across PAD contexts, particularly after some endovascular procedures or in younger revascularized cohorts, where harm signals and treatment heterogeneity remain important concerns. In PAD patients with concomitant atrial fibrillation, the mapped literature also supports maintaining indicated oral anticoagulation and suggests DOAC-based strategies may be preferable to warfarin for overall vascular outcomes. Overall, the review supports a selective, risk-stratified approach that balances limb and cardiovascular protection against bleeding risk rather than a uniform escalation of anticoagulation in all PAD patients. Future research should prioritize indication-specific randomized and prospective comparative studies to define optimal regimens for post-intervention PAD, PAD-VTE overlap, and AF-PAD populations, while improving bleeding-risk stratification and real-world implementation.

Keywords: Peripheral artery disease; Anticoagulation therapy; Rivaroxaban; Major adverse limb events; Lower extremity revascularization; Dual pathway inhibition; Major bleeding risk; Venous thromboembolism; Atrial fibrillation; Ankle-brachial index

Review Stats

Get access to the full paper

temporary link or permanent access.

The remaining part of the paper opens after purchase or unlock.

Reference Index (70)
Article views: —
Follow us

© 2026 SAIMSARA Journal Impressum Published by ML in Health Science GbR